Original Article
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2014; 20(47): 17839-17850
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17839
Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis
Yvette Simon, Sonja M Kessler, Katja Gemperlein, Rainer M Bohle, Rolf Müller, Johannes Haybaeck, Alexandra K Kiemer
Yvette Simon, Sonja M Kessler, Alexandra K Kiemer, Department of Pharmacy, Pharmaceutical Biology, Saarland University, 66123 Saarbrücken, Germany
Sonja M Kessler, Johannes Haybaeck, Medical University of Graz, Institute of Pathology, Graz 8036, Austria
Katja Gemperlein, Rolf Müller, Department of Pharmacy, Pharmaceutical Biotechnology, Saarland University and Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), 66123 Saarbrücken, Germany
Rainer M Bohle, Saarland University, Department of Pathology, 66421 Homburg, Germany
Author contributions: Simon Y and Kessler SM contributed equally to this paper; Simon Y, Kessler SM, Haybaeck J and Kiemer AK designed the experiments, analyzed the data and wrote the manuscript; Kiemer AK initiated and directed the study; Kessler SM, Bohle RM and Haybaeck J scored the histological slides; Gemperlein K and Müller R performed GC-MS lipid analyses; all authors had full access to all of the data (including statistical reports and tables) in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Supported by An EASL Sheila Sherlock fellowship and a Bank Austria visiting scientist program fellowship (to Kessler SM)
Correspondence to: Alexandra K Kiemer, PhD, Department of Pharmacy, Pharmaceutical Biology, Saarland University, Campus C2 2, 66123 Saarbrücken, Germany. pharm.bio.kiemer@mx.uni-saarland.de
Telephone: +49-681-30257301 Fax: +49-681-30257302
Received: April 11, 2014
Revised: June 15, 2014
Accepted: July 11, 2014
Published online: December 21, 2014
Abstract

AIM: To characterize how insulin-like growth factor 2 (IGF2) mRNA binding protein p62/IMP2-2 promotes steatohepatitis in the absence of dietary cholesterol.

METHODS: Non-alcoholic steatohepatitis (NASH) was induced in wild-type mice and in mice overexpressing p62 specifically in the liver by feeding the mice a methionine and choline deficient (MCD) diet for either two or four weeks. As a control, animals were fed a methionine and choline supplemented diet. Serum triglycerides, cholesterol, glucose, aspartate aminotransferase and alanine transaminase were determined by standard analytical techniques. Hepatic gene expression was determined by real-time reverse transcription-polymerase chain reaction. Generation of reactive oxygen species in liver tissue was quantified as thiobarbituric acid reactive substances using a photometric assay and malondialdehyde as a standard. Tissue fatty acid profiles and cholesterol levels were analyzed by gas chromatography-mass spectrometry after hydrolysis. Hepatocellular iron accumulation was determined by Prussian blue staining in paraffin-embedded formalin-fixed tissue. Filipin staining on frozen liver tissue was used to quantify hepatic free cholesterol levels. Additionally, nuclear localization of the nuclear factor kappa B (NF-κB) subunit p65 was examined in frozen tissues.

RESULTS: Liver-specific overexpression of the insulin-like growth factor 2 mRNA binding protein 2-2 (IGF2BP2-2/IMP2-2/p62) induces steatosis with regular chow and amplifies NASH-induced fibrosis in the MCD mouse model. Activation of NF-κB and expression of NF-κB target genes suggested an increased inflammatory response in p62 transgenic animals. Analysis of hepatic lipid composition revealed an elevation of monounsaturated fatty acids as well as increased hepatic cholesterol. Moreover, serum cholesterol was significantly elevated in p62 transgenic mice. Dietary cholesterol represents a critical factor for the development of NASH from hepatic steatosis. Filipin staining revealed increased free cholesterol in p62 transgenic livers, which were not diet-derived. The mRNA levels of the rate-limiting enzyme for cholesterol synthesis 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase or HMGCR) were not significantly upregulated, potentially due to increased cholesterol biosynthesis via elevated sterol regulatory element binding transcription factor 2 (SREBF2) gene expression and increased iron deposition in transgenic animals.

CONCLUSION: This study provides evidence that p62/IGF2BP2-2 drives the progression of NASH through elevation of hepatic iron deposition and increased production of hepatic free cholesterol.

Keywords: Insulin-like growth factor 2 mRNA binding protein 2-2, Methionine/choline deficient, Non-alcoholic fatty liver disease, Filipin, Iron

Core tip: Dietary cholesterol represents a critical factor for the development of non-alcoholic steatohepatitis (NASH) from steatosis. Liver-specific overexpression of the insulin-like growth factor 2 mRNA binding protein p62/IMP2-2/IGF2BP2-2 induces steatosis and amplifies NASH-induced fibrosis. Here, we show that p62 elevates monounsaturated fatty acids and hepatic cholesterol in the absence of exogenous cholesterol. Filipin staining demonstrates increased free cholesterol in p62 transgenic livers. Srebf2-induced cholesterol biosynthesis in transgenics is most likely due to pronounced hepatic iron accumulation, which is also associated with lipid peroxidation in transgenic livers. In summary, p62/IGF2BP2-2 drives the progression of NASH by increasing hepatic free cholesterol.